

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 March 2024 (07.03.2024)



(10) International Publication Number
WO 2024/050138 A3

(51) International Patent Classification:

A61K 39/395 (2006.01) A61K 47/14 (2017.01)
A61K 9/127 (2006.01) A61P 35/00 (2006.01)
A61K 31/7088 (2006.01)

(21) International Application Number:

PCT/US2023/031925

(22) International Filing Date:

02 September 2023 (02.09.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/403,449 02 September 2022 (02.09.2022) US
63/403,454 02 September 2022 (02.09.2022) US
63/403,455 02 September 2022 (02.09.2022) US

(71) Applicant: **MYELOID THERAPEUTICS, INC.**
[US/US]; 300 Technology Square, Suite 203, Cambridge,
Massachusetts 02139 (US).

(72) Inventors: **GETTS, Daniel**; c/o Myeloid Therapeutics,
Inc., 300 Technology Sq, Suite 203, Cambridge, Massachu-
setts 02139 (US). **WANG, Yuxiao**; c/o Myeloid Therapeu-
tics, Inc., 300 Technology Sq, Suite 203, Cambridge, Mass-

achusetts 02139 (US). **DIWANJI, Neha**; c/o Myeloid Ther-
apeutics, Inc., 300 Technology Sq, Suite 203, Cambridge,
Massachusetts 02139 (US).

(74) Agent: **GHOSH, Sanjukta**; Wilson Sonsini Goodrich &
Rosati, 650 Page Mill Road, Palo Alto, California 94304
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: COMPOSITIONS FOR CELL-SPECIFIC EXPRESSION AND USES THEREOF




FIG. 2B

(57) Abstract: Compositions and methods for making and using engineered NK cells, T cells and B cells that express a chimeric antigen receptor.

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

25 April 2024 (25.04.2024)